Nasdaq delisting and OTC trading
Reduced exchange access can lower liquidity, coverage, and financing flexibility.
- Scope
- Common stock trading and capital raising
- Materiality
- high
Synlogic, Inc.
Synlogic, Inc. is a U.S.-based biopharmaceutical company organized around engineered bacterial therapeutics and related research programs. The company was originally built to develop treatments for rare metabolic disorders and operates through Synlogic, Inc. and its subsidiaries from the United States.
−100,0 %
4.30
4.30
| % | |
|---|---|
| Clinical-stage therapeutic programs | 0% Drug candidates and platform programs aimed at treating rare metabolic diseases. |
| Collaborative research and consulting | 100% Non-product arrangements such as material transfer and consulting work. |
Synlogic's direct customers have historically been collaboration partners, research counterparties, and other strategic...
- Strategic transaction counterpartiesprimary
Companies or investors evaluating a merger, sale, or other strategic transaction.
- Pharmaceutical collaboration partnerssecondary
Partners that may license, fund, or co-develop therapeutic assets or platform capabilities.
- Research and consulting clientssecondary
Counterparties purchasing limited scientific or consulting services under non-product agreements.
- Rare disease patients and physiciansemerging
The intended end users of the company's metabolic disorder programs, especially PKU and HCU.
Synlogic is headquartered in the United States and its corporate, research, and administrative activities have been...
- •United States is the core operating base and corporate headquarters
- •Clinical development has included global study activity
- •No disclosed commercial manufacturing network
- •Geography matters mainly through trial execution and partner access
The company's stated strategy is centered on pursuing strategic alternatives to enhance stockholder value, including a...
01
Complete a strategic transactionshort-term
The company is focused on maximizing value through a merger, sale, or similar deal.
02
Preserve cash and operating flexibilityshort-term
A lean structure helps extend runway while alternatives are evaluated.
03
Protect intellectual property and asset valuemedium-term
Any transaction value depends on the remaining technology, patents, and know-how.
Synlogic faces high execution risk because it is a non-operating shell company with no commercial product revenue and a...
Non-operating shell company status
The company has substantially wound down operations, limiting standalone business prospects.
- Scope
- Corporate valuation and transaction optionality
- Materiality
- high
Strategic transaction uncertainty
A merger or sale may not be completed or may not deliver expected value.
- Scope
- Stockholder value realization
- Materiality
- high
Biopharmaceutical development failure
Clinical and regulatory outcomes are inherently uncertain and capital intensive.
- Scope
- Legacy therapeutic assets and IP value
- Materiality
- medium
Key-person and operating concentration
A very small team makes the company dependent on a few individuals and advisors.
- Scope
- Corporate continuity and transaction execution
- Materiality
- medium
Purchase warrant liability fair value
Affects other income/expense and net loss
Restructuring and other charges
Affects operating expenses and reported loss
Revenue recognition
Affects comparability of legacy collaboration periods
R&D expense estimation
Affects operating expense trend analysis
: 29.4.2026